TIGIT (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "TIGIT" in English language version.

refsWebsite

Global rank English rank

17nih.gov

4^th place

12doi.org

2^nd place

6roche.com

low place

4semanticscholar.org

11^th place

8^th place

3worldcat.org

5^th place

2ensembl.org

1,626^th place

1,007^th place

2harvard.edu

18^th place

17^th place

2fiercebiotech.com

low place

8,828^th place

2ascopubs.org

low place

1youtube.com

9^th place

13^th place

1onclive.com

low place

1annalsofoncology.org

low place

1evaluate.com

low place

1oncologypipeline.com

low place

annalsofoncology.org (Global: low place; English: low place)

Cho BC, Rodriguez-Abreu D, Hussein M, Cobo M, Patel A, Secen N, Gerstner G, Kim DW, Lee YG, Su WC, Huang E (2021-12-01). "LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC". Annals of Oncology. 32: S1428. doi:10.1016/j.annonc.2021.10.217. ISSN 0923-7534. S2CID 245059452.

ascopubs.org (Global: low place; English: low place)

Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne A, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Rao Edubilli T, Gane E (2023-06-01). "Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)". Journal of Clinical Oncology. 41 (16_suppl): 4010. doi:10.1200/JCO.2023.41.16_suppl.4010. ISSN 0732-183X. S2CID 259083998.
Rudin CM, Liu SV, Lu S, Soo RA, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Navarro A, Novello S, Ozawa Y, Meng R (2022-06-10). "SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)". Journal of Clinical Oncology. 40 (17_suppl) LBA8507. doi:10.1200/JCO.2022.40.17_suppl.LBA8507. ISSN 0732-183X.

doi.org (Global: 2^nd place; English: 2^nd place)

Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, Eaton D, Grogan JL (Jan 2009). "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells". Nat Immunol. 10 (1): 48–57. doi:10.1038/ni.1674. PMID 19011627. S2CID 205361984.
Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M (Mar 2009). "A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC". European Journal of Immunology. 39 (3): 695–703. doi:10.1002/eji.200839116. PMC 3544471. PMID 19197944.
Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM, et al. (April 2011). "Vstm3 is a member of the CD28 family and an important modulator of T-cell function". European Journal of Immunology. 41 (4): 902–15. doi:10.1002/eji.201041136. PMC 3733993. PMID 21416464.
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J (2021-07-22). "TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer". Frontiers in Immunology. 12 699895. doi:10.3389/fimmu.2021.699895. PMC 8339559. PMID 34367161.
Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O (Oct 2009). "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity". Proc Natl Acad Sci U S A. 106 (42): 17858–63. Bibcode:2009PNAS..10617858S. doi:10.1073/pnas.0903474106. PMC 2764881. PMID 19815499.
Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. (Jan 2016). "TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection". PLOS Pathogens. 12 (1) e1005349. doi:10.1371/journal.ppat.1005349. PMC 4704737. PMID 26741490.
Steven G. Deeks (July 2012). "HIV: Shock and Kill". Nature. 487 (1): 439–440. Bibcode:2012Natur.487..439D. doi:10.1038/487439a. PMID 22836995. S2CID 205073070.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour (April 2015). "TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients". J Clin Invest. 125 (5): 2046–2058. doi:10.1172/JCI80445. PMC 4463210. PMID 25866972.
Robert J. Johnston, Laetitia Comps-Agrar, Jason Hackney, Xin Yu, Mahrukh Huseni, Yagai Yang, Summer Park, Vincent Javinal, Henry Chiu, Bryan Irving, Dan L. Eaton, Jane L. Grogan (December 2014). "The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function". Cancer Cell. 26 (6): 923–937. doi:10.1016/j.ccell.2014.10.018. PMID 25465800.
Cho BC, Rodriguez-Abreu D, Hussein M, Cobo M, Patel A, Secen N, Gerstner G, Kim DW, Lee YG, Su WC, Huang E (2021-12-01). "LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC". Annals of Oncology. 32: S1428. doi:10.1016/j.annonc.2021.10.217. ISSN 0923-7534. S2CID 245059452.
Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne A, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Rao Edubilli T, Gane E (2023-06-01). "Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)". Journal of Clinical Oncology. 41 (16_suppl): 4010. doi:10.1200/JCO.2023.41.16_suppl.4010. ISSN 0732-183X. S2CID 259083998.
Rudin CM, Liu SV, Lu S, Soo RA, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Navarro A, Novello S, Ozawa Y, Meng R (2022-06-10). "SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)". Journal of Clinical Oncology. 40 (17_suppl) LBA8507. doi:10.1200/JCO.2022.40.17_suppl.LBA8507. ISSN 0732-183X.

ensembl.org (Global: 1,626^th place; English: 1,007^th place)

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000181847 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000071552 – Ensembl, May 2017

evaluate.com (Global: low place; English: low place)

"Looking beyond Roche's Tigit bombshell". Evaluate.com. 2022-05-11. Retrieved 2024-01-20.

fiercebiotech.com (Global: low place; English: 8,828^th place)

Adams B (2021-11-10). "Roche posts 'impressive' TIGIT combo lung cancer data, but trial deaths weigh down shares". Fierce Pharma. Retrieved 2023-10-13.
"Roche stops pivotal TIGIT trial after Keytruda lands knockout blow at first attempt". Fierce Biotech. 4 July 2024.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O (Oct 2009). "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity". Proc Natl Acad Sci U S A. 106 (42): 17858–63. Bibcode:2009PNAS..10617858S. doi:10.1073/pnas.0903474106. PMC 2764881. PMID 19815499.
Steven G. Deeks (July 2012). "HIV: Shock and Kill". Nature. 487 (1): 439–440. Bibcode:2012Natur.487..439D. doi:10.1038/487439a. PMID 22836995. S2CID 205073070.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, Eaton D, Grogan JL (Jan 2009). "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells". Nat Immunol. 10 (1): 48–57. doi:10.1038/ni.1674. PMID 19011627. S2CID 205361984.
Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M (Mar 2009). "A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC". European Journal of Immunology. 39 (3): 695–703. doi:10.1002/eji.200839116. PMC 3544471. PMID 19197944.
Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM, et al. (April 2011). "Vstm3 is a member of the CD28 family and an important modulator of T-cell function". European Journal of Immunology. 41 (4): 902–15. doi:10.1002/eji.201041136. PMC 3733993. PMID 21416464.
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J (2021-07-22). "TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer". Frontiers in Immunology. 12 699895. doi:10.3389/fimmu.2021.699895. PMC 8339559. PMID 34367161.
Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O (Oct 2009). "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity". Proc Natl Acad Sci U S A. 106 (42): 17858–63. Bibcode:2009PNAS..10617858S. doi:10.1073/pnas.0903474106. PMC 2764881. PMID 19815499.
Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. (Jan 2016). "TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection". PLOS Pathogens. 12 (1) e1005349. doi:10.1371/journal.ppat.1005349. PMC 4704737. PMID 26741490.
Steven G. Deeks (July 2012). "HIV: Shock and Kill". Nature. 487 (1): 439–440. Bibcode:2012Natur.487..439D. doi:10.1038/487439a. PMID 22836995. S2CID 205073070.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour (April 2015). "TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients". J Clin Invest. 125 (5): 2046–2058. doi:10.1172/JCI80445. PMC 4463210. PMID 25866972.
Robert J. Johnston, Laetitia Comps-Agrar, Jason Hackney, Xin Yu, Mahrukh Huseni, Yagai Yang, Summer Park, Vincent Javinal, Henry Chiu, Bryan Irving, Dan L. Eaton, Jane L. Grogan (December 2014). "The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function". Cancer Cell. 26 (6): 923–937. doi:10.1016/j.ccell.2014.10.018. PMID 25465800.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M (Mar 2009). "A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC". European Journal of Immunology. 39 (3): 695–703. doi:10.1002/eji.200839116. PMC 3544471. PMID 19197944.
Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM, et al. (April 2011). "Vstm3 is a member of the CD28 family and an important modulator of T-cell function". European Journal of Immunology. 41 (4): 902–15. doi:10.1002/eji.201041136. PMC 3733993. PMID 21416464.
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J (2021-07-22). "TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer". Frontiers in Immunology. 12 699895. doi:10.3389/fimmu.2021.699895. PMC 8339559. PMID 34367161.
Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O (Oct 2009). "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity". Proc Natl Acad Sci U S A. 106 (42): 17858–63. Bibcode:2009PNAS..10617858S. doi:10.1073/pnas.0903474106. PMC 2764881. PMID 19815499.
Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. (Jan 2016). "TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection". PLOS Pathogens. 12 (1) e1005349. doi:10.1371/journal.ppat.1005349. PMC 4704737. PMID 26741490.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour (April 2015). "TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients". J Clin Invest. 125 (5): 2046–2058. doi:10.1172/JCI80445. PMC 4463210. PMID 25866972.

onclive.com (Global: low place; English: low place)

Pharmaceutical Leaders Highlight Promise of TIGIT. Feb 2017

oncologypipeline.com (Global: low place; English: low place)

Plieth J. "Another twist in the TIGIT saga". ApexOnco. Retrieved 2023-10-12.

roche.com (Global: low place; English: low place)

roche.com

"[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer". Roche (Press release). Retrieved 2023-10-12.
"[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer". www.roche.com (Press release). Retrieved 2023-10-12.
"[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer". Roche. 4 July 2024.

medically.roche.com

Salani R (2023-11-05). "Efficacy and safety results from SKYSCRAPER-04: An open-label randomized phase 2 trial of tiragolumab plus atezolizumab for PD-L1-positive recurrent cervical cancer". medically.roche.com. Retrieved 2024-01-20.
Hsu CH (2024-01-18). "SKYSCRAPER-08: a phase III, randomized, double-blind, placebo-controlled study of first-line tiragolumab + atezolizumab and chemotherapy in patients with esophageal squamous cell carcinoma". medically.roche.com. Retrieved 2024-01-20.
Sun JM (2024-01-18). "MORPHEUS-EC: a phase Ib/II open-label, randomized study of tiragolumab plus atezolizumab plus chemotherapy in patients with previously untreated locally advanced unresectable or metastatic esophageal cancer". medically.roche.com. Retrieved 2024-01-20.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, Eaton D, Grogan JL (Jan 2009). "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells". Nat Immunol. 10 (1): 48–57. doi:10.1038/ni.1674. PMID 19011627. S2CID 205361984.
Steven G. Deeks (July 2012). "HIV: Shock and Kill". Nature. 487 (1): 439–440. Bibcode:2012Natur.487..439D. doi:10.1038/487439a. PMID 22836995. S2CID 205073070.
Cho BC, Rodriguez-Abreu D, Hussein M, Cobo M, Patel A, Secen N, Gerstner G, Kim DW, Lee YG, Su WC, Huang E (2021-12-01). "LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC". Annals of Oncology. 32: S1428. doi:10.1016/j.annonc.2021.10.217. ISSN 0923-7534. S2CID 245059452.
Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne A, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Rao Edubilli T, Gane E (2023-06-01). "Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)". Journal of Clinical Oncology. 41 (16_suppl): 4010. doi:10.1200/JCO.2023.41.16_suppl.4010. ISSN 0732-183X. S2CID 259083998.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Cho BC, Rodriguez-Abreu D, Hussein M, Cobo M, Patel A, Secen N, Gerstner G, Kim DW, Lee YG, Su WC, Huang E (2021-12-01). "LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC". Annals of Oncology. 32: S1428. doi:10.1016/j.annonc.2021.10.217. ISSN 0923-7534. S2CID 245059452.
Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne A, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Rao Edubilli T, Gane E (2023-06-01). "Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)". Journal of Clinical Oncology. 41 (16_suppl): 4010. doi:10.1200/JCO.2023.41.16_suppl.4010. ISSN 0732-183X. S2CID 259083998.
Rudin CM, Liu SV, Lu S, Soo RA, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Navarro A, Novello S, Ozawa Y, Meng R (2022-06-10). "SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)". Journal of Clinical Oncology. 40 (17_suppl) LBA8507. doi:10.1200/JCO.2022.40.17_suppl.LBA8507. ISSN 0732-183X.

youtube.com (Global: 9^th place; English: 13^th place)

"Lung Cancer and Immunotherapy with Dr. Patrick Forde and Oswald Peterson". YouTube. October 22, 2021. Retrieved 5 July 2022.

TIGIT (English Wikipedia)

annalsofoncology.org (Global: low place; English: low place)

ascopubs.org (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 1,626th place; English: 1,007th place)

May2017.archive.ensembl.org

evaluate.com (Global: low place; English: low place)

fiercebiotech.com (Global: low place; English: 8,828th place)

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

onclive.com (Global: low place; English: low place)

oncologypipeline.com (Global: low place; English: low place)

roche.com (Global: low place; English: low place)

roche.com

medically.roche.com

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

youtube.com (Global: 9th place; English: 13th place)

doi.org (Global: 2^nd place; English: 2^nd place)

ensembl.org (Global: 1,626^th place; English: 1,007^th place)

fiercebiotech.com (Global: low place; English: 8,828^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

nih.gov (Global: 4^th place; English: 4^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

worldcat.org (Global: 5^th place; English: 5^th place)

youtube.com (Global: 9^th place; English: 13^th place)